Immune-Onc Therapeutics

Focus: Immune-Onc Therapeutics is a newly founded (2024) immuno-oncology biotech company headquartered in Palo Alto, CA, focused on developing novel cancer immunotherapies. The company is pre-revenue with an early-stage pipeline in Phase 1 development.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Immune-Onc Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Immune-Onc Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

NEUTREXIN

Pneumocystis Carinii Pneumonia, HIV Infections

LOE Approaching

Legacy NDA product with approaching loss of exclusivity; likely not a material revenue driver for company strategy.

Products & Portfolio (1)

Help build intelligence for Immune-Onc Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded company (2024) in the high-growth immuno-oncology space with potential for significant equity upside
Access to emerging pipeline candidates (IO-108, IO-202) in solid tumors and hematologic malignancies at the formative stage
Based in Palo Alto biotech hub with proximity to top talent, investors, and industry networks

Watch Out For

Pre-revenue stage with no disclosed funding, cash position, or employment size creates significant financial and operational uncertainty
Only 3 Phase 1 trials across entire pipeline with no Phase 2/3 programs means limited near-term clinical validation or commercialization catalysts
Zero active job openings at time of analysis suggests company may not be actively scaling or may be in stealth mode

Generated by Claude from Immune-Onc Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.